

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



BeiGene, Ltd.

百濟神州有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 06160)

DATE OF AUDIT COMMITTEE MEETING

BeiGene, Ltd. (the “**Company**”) hereby announces that a meeting of the audit committee of the board of directors (the “**Board**”) will be held on Wednesday May 4, 2022 (U.S. Eastern Time) for the purposes of, inter alia, considering and approving the results of the Company and its subsidiaries for the three months ended March 31, 2022 prepared in accordance with U.S. Generally Accepted Accounting Principles and the applicable rules of the U.S. Securities and Exchange Commission and its publication. The Company expects to announce its financial results for the three months ended March 31, 2022 before the open of U.S. financial markets on Thursday May 5, 2022.

By order of the Board
BeiGene, Ltd.
Mr. John V. Oyler
Chairman

Hong Kong, April 21, 2022

As of the date of this announcement, the Board of Directors of the Company comprises Mr. John V. Oyler as Chairman and Executive Director, Dr. Xiaodong Wang and Mr. Anthony C. Hooper as Non-executive Directors, and Mr. Timothy Chen, Dr. Margaret Han Dugan, Mr. Donald W. Glazer, Mr. Michael Goller, Mr. Ranjeev Krishana, Mr. Thomas Malley, Dr. Alessandro Riva, Dr. Corazon (Corsee) D. Sanders and Mr. Qingqing Yi as Independent Non-executive Directors.